4-Oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3238-3247

  Villani, Maria Grazia ^a   Appierto, Valentina ^a   Cavadini, Elena ^a   Bettiga, Arianna ^b   Prinetti, Alessandro ^b   Clagett Dame, Margaret ^c   Curley, Robert W ^d   Formelli, Franca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXOFENRETINIDE; CASPASE 3; CASPASE 8; CASPASE 9; CERAMIDE; CYCLIN DEPENDENT KINASE 1; DRUG METABOLITE; FENRETINIDE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LINE; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERAMIDES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; FENRETINIDE; G2 PHASE; HUMANS; NEUROBLASTOMA; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 33645511417     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3362     Document Type: Article

References (49)

1. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
3. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
4. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004;24:201-21.
5. Sun SY, Hail N, Jr., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96:662-72.
6. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
7. De Palo G, Mariani L, Camerini T, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002;86:24-7.
8. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma Clin Cancer Res 2003;9:2032-9.
9. Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol 1992;28:97-102.
10. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005; 115:625-9.
11. Tradati N, Chiesa F, Rossi N, et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994;76:109-11.
12. Moglia D, Formelli F, Baliva G, et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett 1996;110:87-91.
13. Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J 1996;10:1014-24.
14. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:22441-6.
15. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:14-8.
16. Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997;18:943-8.
17. Hail N, Jr., Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem 2001;276:45614-21.
18. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001;61:5102-5.
19. Prinetti A, Basso L, Appierto V, et al. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 2003;278:5574-83.
20. Villani MG, Appierto V, Cavadini E, et al. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 2004;10:6265-75.
21. Appierto V, Cavadini E, Pergolizzi R, et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer 2001;84:1528-34.
22. Mehta RR, Hawthorne ME, Graves JM, Mehta RG. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur J Cancer 1998;34:902-7.
23. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
24. Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ. Combination chemotherapy in vitro with Adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1976;1:187-95.
25. Clagett-Dame M, Repa JJ. Methods for generating and characterizing retinoid receptors from E. coli and insect cell expression systems. Methods Enzymol 1997; 282:13-24.
26. Supino R, Crosti M, Clerici M, et al. Induction of apoptosis by fenretinide (4-HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996; 65:491-7.
27. Prinetti A, Chigorno V, Prioni S, et al. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J Biol Chem 2001; 276:21136-45.
28. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
29. Toth B, Ludanyi K, Kiss I, et al. Retinoids induce Fas(CD95) ligand cell surface expression via RAR-gamma and nur77 in T cells. Eur J Immunol 2004;34:827-36.
30. Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991;27:138-41.
31. Formelli F, Carsana R, Costa A, et al. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 1989;49:6149-52.
32. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42.
33. Achkar CC, Derguini F, Blumberg B, et al. 4-Oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors. Proc Natl Acad Sci U S A 1996;93:4879-84.
34. Idres N, Benoit G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans-retinoic acid metabolites. Cancer Res 2001;61:700-5.
35. Formelli F, Cleris L. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur J Cancer 2000;36:2411-9.
36. Sabichi AL, Xu H, Fischer S, et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 2003;9:4606-13.
37. Holmes WF, Soprano DR, Soprano KJ. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J Cell Physiol 2004;199:317-29.
38. Takahashi N, Sausville EA, Breitman TR. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins. Clin Cancer Res 1995; 1:637-42.
39. 2/M cell cycle transition. FEBS Lett 1999;444:32-7.
40. Delia D, Aiello A, Formelli F, et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 1995; 85:359-67.
41. Zou C, Liebert M, Zou C, Grossman HB, Lotan R. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J Urol 2001;165:986-92.
42. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999;55:403-10.
43. Broaddus RR, Xie S, Hsu CJ, Wang J, Zhang S, Zou C. The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas. Am J Obstet Gynecol 2004;190:686-92.
44. Brewer M, Wharton JT, Wang J, et al. In vitro model of normal immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 2005;98:182-92.
45. Kalli KR, Devine KE, Cabot MC, et al. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 2003;64:1434-43.
46. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169-80.
47. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004;64:5415-24,
48. Pergolizzi R, Appierto V, Crosti M, et al. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 1999;81:829-34.
49. Repa JJ, Plum LA, Tadikonda PK, Clagett-Dame M. All-trans 3,4-didehydroretinoic acid equals all-trans retinoic acid in support of chick neuronal development. FASEB J 1996;10:1078-84.